The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research. In ...

LDH is a well-accepted biomarker of intravascular hemolysis that measures how effective a treatment is at inhibiting the destruction of red blood cells and has also demonstrated a correlation to ...

Medically reviewed by Jordana Haber Hazan, MD Hemolytic anemia occurs when red blood cells are destroyed faster than they can ...

Babesiosis, a tickborne zoonotic disease caused by intraerythrocytic protozoa of the genus babesia, is characterized by nonimmune hemolytic anemia that resolves with antimicrobial treatment and ...

A novel drug combination, improvements in quality of life, and breakthrough hemolysis control are among the clinical highlights in paroxysmal nocturnal hemoglobinuria (PNH) presented at the 2024 ...

Hemolysis is the #1 source of preanalytical error and can impact potassium results—potentially leading to inappropriate or delayed patient treatment, unnecessary ...

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common inherited enzyme disorders, affecting hundreds of millions worldwide. This condition results from mutations in the G6PD ...

Anemia and hemolytic anemia are both conditions that result in too few red blood cells (RBCs). Their causes are different, but both have similar symptoms and can lead to long-term complications. Share ...